Advertisement

The Indian Journal of Pediatrics

, Volume 70, Issue 7, pp 585–586 | Cite as

Controversies in BCG immunization

  • A. Parthasarathy
Symposium on Controversies in Immunization-II

Abstract

Despite controversies BCG vaccination has stood the test of time. World Health Organization continues to recommend its use in infant immunization programme in countries with heavy endemicity and where threatening HIV epidemic in an emerging problem >85% efficacy have been established in recent years against hematogenous spread of the disease and ≥50% efficacy even against pulmonary tuberculosis. Host related factors, agent related factors, vaccine related factors and inadequacy of evaluation tests determine the BCG vaccine efficacy. Identification of complete BCG genome in 1998 has opened new vistas in newer BCG vaccine development. Adoption of a ’5C concept viz. Case detection, Chemotherapy short course, Contact elimination, Chemoprophylaxis and lastly control in BCG vaccine will be a desirable national approach in combating adult and childhood TB.

Key words

BCG immunizationc Field efficacy Controversies 

References

  1. 1.
    American Academy of Pediatrics. Tuberculosis-BCG vaccine. In Pickering LK, ed.2000 Red Book; Report of the Committee on Infectious Diseases. 25th edn. Elk Grove Village, II: American Academy of Pediatrics; 2000: 612.Google Scholar
  2. 2.
    McMurray DN. Disease Model-Pulmonary Tuberculosis.Trends Mol Med 2001; 7(3): 135–137.PubMedCrossRefGoogle Scholar
  3. 3.
    Mukesh Agrawal. BCG vaccine. Immunization for Children. In Niranjan Shenduchikar. Mukesh Agrawal, eds.Immunization for Children; Paras Publishing. Hyderabad-Bangalore 2001; 20.Google Scholar
  4. 4.
    Andersen P. vaccines: Progress and Problems.Trends Immunol 2001; 22(3): 160–168PubMedCrossRefGoogle Scholar
  5. 5.
    Young DB. Current Tuberculosis Vaccine Development.Clin Infect Dis 2000; 30 (Suppl. 3): S254–256.PubMedCrossRefGoogle Scholar
  6. 6.
    Doherty TM, Anderson P. Tuberculosis Vaccines: Development Work and the future.Curr Opin Pulm Med 2000; 6:203–208.PubMedCrossRefGoogle Scholar
  7. 7.
    McMurray DN, Recent advances is improved tuberculosis vaccines.Indian J Pediatr 2000; 67(S), S58–62PubMedGoogle Scholar
  8. 8.
    Dreher D, Kok M, Pechere JCet al. New Strategies Against Old Plague: Genetically Engineered Tuberculosis Vaccines. Schweizerische NMedizinische Wochenschrift.J Suisse Med 2000; 130 (50): 1925–1929.Google Scholar
  9. 9.
    Thole JE, Van Dalen PJ, Havenith CEet al. Live Bacterial Delivery systems for Development of Mucosal Vaccines.Curr Opin Mol Therap 2000; 2(1): 94–99.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2003

Authors and Affiliations

  • A. Parthasarathy
    • 1
  1. 1.Chennai

Personalised recommendations